Belsomra (suvorexant) entered the US sleep-aid market almost a decade ago, and was recently joined by Dayvigo (lemborexant) and Quviviq (daridorexant). All of these agents work to block orexin receptors in the brain, a distinctively different mechanism than other sleeping pills. Despite several distinct advantages over other classes of sleeping agents, sales have not been spectacular. But recent discoveries, particularly a suggestion that suvorexant may reduce the amyloid Beta plaques and Tau fibrillary tangles that are hallmarks of Alzheimer's Dementia has driven up attention. Experts think that these agents may also have a role in treating depression, anxiety and ADHD.
12 июн 2023
